-
-
-
-
-
-
-
KalVista reports $49.1 million EKTERLY revenue in eight-month period
-
-
-
-
-
-
-
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
-
-
-
-
-
-
-
KalVista presents patient satisfaction data for EKTERLY at ACAAI meeting
-
-
-
-
-
-
-
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
-
-
-
-
-
-
-
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
-
-
-
-
-
-
-
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
-
-
-
-
-
-
-
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
-
1,197,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

